Gómez-Vázquez HM

Language: Spanish
References: 19
Page: 645-649
PDF size: 500.90 Kb.

ABSTRACT

Objective: To measure what percentage of patients has a QTc›450, it means, prolonged.
Material and method: An observational, prospective study in which an electrocardiogram and formula of QTc were done by Bazett formula in 150 consecutive patients of Internal Medicine consultation, older than 40 years, in which physician found any indication to perform a ECG tracing.
Results: In 15 consecutive patients it was found a mean QTc of 425.69, range: 357-511 and normal distribution, 20 patients (13%) had a QTc ≥ 450.
Conclusions: Due to it was found a prolonged QTc in 13% of consecutive stable patients, it is concluded that we always should measure the interval before prescribing azithromycin or clarithromycin, although the risk for each opportunity of prescription is low.

REFERENCES

1. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, et al. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia. Respir Med 2012;106:451-458.

2. Albert R, Connett J, Bailey W, Casaburi R, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-698.

3. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, CAP Working Group. Summary of the Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J 2000;7:371-382.

4. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615.

5. Mortensen EM, Halm EA, Pugh M, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia JAMA 2014;311:2199-2298.

6. Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2014;368:1665-1668.

7. Ray WA, Murray KT, Meredith S, Narasimhulu SS, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-1890.

8. COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-698.

9. Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015;147:894-942.

10. Postma DF, Werkhoven CH, van Elden LJ, Thijsen SF, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372:1312-1323.

11. Svanström HM, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013;368:1704-1712.

12. Wenzel RP, Fowler AA 3rd, Edmond MB. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med 2012;367:340-347.

13. Abu-Gharbieh E, Vasina V, Poluzzi E, De Ponti F. Antibacterial macrolides: a drug class with a complex pharmacological profile. Pharmacol Res 2004;50:211-222.

14. Kertland H. Should azithromycin no longer be considered a drug of choice for community-acquired pneumonia because of its potential to cause cardiovascular death? Can J Hosp Pharm 2013;66:328-331.

15. Wenzel RP, Fowler A, Edmond M. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med 2012;367:340-347.

16. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, et al. Long-term erithromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-1147.

17. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3:331-350.

18. Milstone A. Use of azithromycin in the treatment of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2008;3:515-520.

19. Barbara AL, David NJ. Drugs and the QT interval — Caveat Doctor. N Engl J Med 2004;351:1053-1056.